Wu CJ - Search Results

1

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.

Lee PC, Wu CJ, Hung YW, Lee CJ, Chi CT, Lee IC, Yu-Lun K, Chou SH, Luo JC, Hou MC, Huang YH. Lee PC, et al. Among authors: wu cj. J Immunother Cancer. 2022 Jun;10(6):e004779. doi: 10.1136/jitc-2022-004779. J Immunother Cancer. 2022. PMID: 35738801 Free PMC article.

2

Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy.

Wu CJ, Chau GY, Lee IC, Huo TI, Su CW, Hou MC, Huang YH. Wu CJ, et al. J Formos Med Assoc. 2021 Aug;120(8):1563-1571. doi: 10.1016/j.jfma.2020.11.019. Epub 2020 Dec 15. J Formos Med Assoc. 2021. PMID: 33334659 Free article.

3

Predictors of long-term recurrence and survival after resection of HBV-related hepatocellular carcinoma: the role of HBsAg.

Lee IC, Lei HJ, Chau GY, Yeh YC, Wu CJ, Su CW, Huo TI, Chao Y, Lin HC, Hou MC, Huang YH. Lee IC, et al. Among authors: wu cj. Am J Cancer Res. 2021 Jul 15;11(7):3711-3725. eCollection 2021. Am J Cancer Res. 2021. PMID: 34354870 Free PMC article.

4

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma.

Wu CJ, Lee PC, Hung YW, Lee CJ, Chi CT, Lee IC, Hou MC, Huang YH. Wu CJ, et al. Cancer Immunol Immunother. 2022 Nov;71(11):2631-2643. doi: 10.1007/s00262-022-03185-6. Epub 2022 Mar 28. Cancer Immunol Immunother. 2022. PMID: 35347395 Free PMC article.

5

Determinants of Survival and Post-Progression Outcomes by Sorafenib-Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma.

Lee IC, Chao Y, Lee PC, Chen SC, Chi CT, Wu CJ, Wu KC, Hou MC, Huang YH. Lee IC, et al. Among authors: wu kc, wu cj. Cancers (Basel). 2022 Apr 15;14(8):2014. doi: 10.3390/cancers14082014. Cancers (Basel). 2022. PMID: 35454919 Free PMC article.

6

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment.

Lee IC, Lee PC, Chao Y, Chi CT, Wu CJ, Hung YP, Su CW, Hou MC, Huang YH. Lee IC, et al. Among authors: wu cj. Viruses. 2022 Oct 26;14(11):2355. doi: 10.3390/v14112355. Viruses. 2022. PMID: 36366452 Free PMC article.

7

Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy.

Mon HC, Lee PC, Hung YP, Hung YW, Wu CJ, Lee CJ, Chi CT, Lee IC, Hou MC, Huang YH. Mon HC, et al. Among authors: wu cj. J Hepatol. 2024 Jul 29:S0168-8278(24)02425-5. doi: 10.1016/j.jhep.2024.07.018. Online ahead of print. J Hepatol. 2024. PMID: 39084471 Free article.

8

Impact of HCV eradication on recurrence pattern and long-term outcomes in patients with HCV-related hepatocellular carcinoma undergoing radiofrequency ablation.

Wu KC, Lee IC, Chi CT, Liu CA, Chiu NC, Hsu SJ, Lee PC, Wu CJ, Luo JC, Hou MC, Huang YH. Wu KC, et al. Among authors: wu cj. Aliment Pharmacol Ther. 2024 Oct;60(7):940-952. doi: 10.1111/apt.18199. Epub 2024 Aug 7. Aliment Pharmacol Ther. 2024. PMID: 39113355

9

Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.

Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, Eguchi S, Yoshizumi T, Itoh S, Nakamura N, Kosaka H, Kaibori M, Ishii T, Hatano E, Ogawa C, Naganuma A, Kakizaki S, Cheng CH, Lin PT, Su YY, Chuang CH, Lu LC, Wu CJ, Wang HW, Rau KM, Hsu CH, Lin SM, Huang YH, Hernandez S, Finn RS, Kudo M, Cheng AL. Shen YC, et al. Among authors: wu cj. J Clin Oncol. 2024 Aug 28:JCO2400645. doi: 10.1200/JCO.24.00645. Online ahead of print. J Clin Oncol. 2024. PMID: 39197119

10

Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression.

Liu TH, Chen SC, Rau KM, Lu LC, Lin PT, Su YY, Teng W, Lai SW, Yeh RH, Kao TM, Lee PC, Wu CJ, Chen CH, Hsu CH, Lin SM, Huang YH, Chen LT, Cheng AL, Shen YC; Taiwan Liver Cancer Association Research Group (TRG). Liu TH, et al. Among authors: wu cj. Liver Cancer. 2024 Feb 1;13(5):509-521. doi: 10.1159/000536549. eCollection 2024 Oct. Liver Cancer. 2024. PMID: 39435270 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,877 results

Search Page

Filters